Sep 3, 2026, 8:30 AM EDT · 4 weeks ago Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-17T09:42:41.000Z · 6 weeks ago Bone Biologics announces extended shelf life for rhNELL-1 protein
Aug 12, 2026, 8:00 AM EDT · 7 weeks ago Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
Jul 23, 2026, 8:00 AM EDT · 2 months ago Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
2026-07-17T21:20:10.000Z · 2 months ago Bone Biologics files to sell 6.46M shares of common stock for holders
Jul 7, 2026, 8:00 PM EDT · 2 months ago Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
May 19, 2026, 8:00 AM EDT · 4 months ago Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
2026-01-08T13:40:29.000Z · 8 months ago Bone Biologics summarizes key milestones achieved during 2025
Jan 8, 2026, 8:00 AM EST · 8 months ago Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
2025-12-23T13:05:40.000Z · 9 months ago Bone Biologics receives confirmation rhNELL-1 shelf life extended to 24 months
Dec 23, 2025, 8:00 AM EST · 9 months ago Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Sep 4, 2025, 7:00 AM EDT · 1 year ago Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
Sep 3, 2025, 7:00 AM EDT · 1 year ago Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
Jun 30, 2025, 4:10 PM EDT · 1 year ago Bone Biologics Announces Closing of $5.0 Million Public Offering
Jun 27, 2025, 9:10 AM EDT · 1 year ago Bone Biologics Announces Pricing of $5.0 Million Public Offering
2025-06-27T11:15:19.000Z · 1 year ago Bone Biologics files NELL-1 protein patent application with USPTO
Jun 27, 2025, 7:00 AM EDT · 1 year ago Bone Biologics Files Patent Application for Bone Regeneration Technology
Jun 26, 2025, 4:20 PM EDT · 1 year ago Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Oct 21, 2024, 8:00 AM EDT · 1 year ago Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
Sep 4, 2024, 8:00 AM EDT · 2 years ago Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-12T21:02:54.000Z · 2 years ago Bone Biologics files to sell 1.62M shares of common stock for holders
Aug 2, 2024, 8:00 AM EDT · 2 years ago Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
2024-06-20T12:11:52.000Z · 2 years ago Bone Biologics treated first two patients in study of NB1 bone graft device
Jun 20, 2024, 8:00 AM EDT · 2 years ago First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion
Mar 6, 2024, 4:15 PM EST · 2 years ago Bone Biologics Announces Closing of $2.0 Million Public Offering
Mar 4, 2024, 9:15 AM EST · 2 years ago Bone Biologics Announces Pricing of $2.0 Million Public Offering
2024-01-30T22:11:20.000Z · 2 years ago Bone Biologics files to sell common stock, warrants, no amount given
Jan 11, 2024, 8:00 AM EST · 2 years ago Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
2024-01-10T13:03:43.000Z · 2 years ago Bone Biologics regains compliance with Nasdaq continued listing rule
2024-01-05T22:18:07.000Z · 2 years ago Bone Biologics files to sell 142,384 shares of common stock for holders
Nov 20, 2023, 12:38 PM EST · 2 years ago Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Nov 16, 2023, 4:43 PM EST · 2 years ago Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Sep 26, 2023, 8:00 AM EDT · 3 years ago Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
Jun 15, 2023, 9:22 AM EDT · 3 years ago Bone Biologics stock plummets more than 50% after stock offering prices at deep discount
Jun 14, 2023, 11:30 PM EDT · 3 years ago Bone Biologics Prices $5.0 Million Underwritten Public Offering
Apr 11, 2023, 8:00 AM EDT · 3 years ago Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Jan 26, 2023, 8:30 AM EST · 3 years ago Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
Oct 13, 2022, 9:00 AM EDT · 3 years ago WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering
Oct 12, 2022, 4:05 PM EDT · 3 years ago Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
Oct 7, 2022, 10:52 AM EDT · 3 years ago CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
Oct 7, 2022, 10:16 AM EDT · 3 years ago WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering
Oct 7, 2022, 8:00 AM EDT · 3 years ago Bone Biologics Prices $5,100,000 Million Underwritten Public Offering
Mar 23, 2022, 8:00 AM EDT · 4 years ago Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 7, 2022, 7:00 AM EST · 4 years ago Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
Jan 5, 2022, 8:30 AM EST · 4 years ago Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference
Oct 18, 2021, 8:30 AM EDT · 4 years ago Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
Oct 15, 2021, 12:00 PM EDT · 4 years ago WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering
Oct 13, 2021, 1:43 PM EDT · 4 years ago WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market
Oct 13, 2021, 12:25 PM EDT · 4 years ago Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split